SCHEMBL2264665

SCHEMBL2264665

Cc1ccc(Cn2c(-c3ccc(Oc4ccccc4)cc3)cc(C(F)(F)F)c(CN(C)C)c2=O)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.51
NR1H3 Q13133 4/20 0.51
RXRA P19793 2/20 0.51
BACE1 P56817 1/20 0.33
SLC6A4 P31645 3/20 0.33
HTR2A P28223 1/20 0.33
MGLL Q99685 2/20 0.32
HPGD P15428 2/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
SLC6A2 P23975 2/20 0.32
SLC6A3 Q01959 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
GNRHR P30968 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263564 0.92 NR1H2 (0.40) NR1H2NR1H3RXRAHPGDALDH1A1
SCHEMBL2261183 0.89 NR1H2 (0.53) NR1H2NR1H3RXRABACE1MGLL
SCHEMBL12390196 0.85 NR1H2 (0.54) NR1H2NR1H3RXRABACE1MGLL
SCHEMBL6215062 0.82 NR1H2 (0.51) NR1H2NR1H3RXRABACE1F11
SCHEMBL2263400 0.81 NR1H2 (0.69) NR1H2NR1H3RXRAHPGDALDH1A1
SCHEMBL1033748 0.81 NR1H2 (0.50) NR1H2NR1H3RXRABACE1HPGD
SCHEMBL6215068 0.81 NR1H2 (0.50) NR1H2NR1H3RXRABACE1
SCHEMBL12366818 0.80 NR1H2 (0.49) NR1H2NR1H3RXRABACE1HPGD
SCHEMBL12366588 0.80 NR1H2 (0.41) NR1H2NR1H3RXRAALDH1A1MAPT
SCHEMBL12389419 0.80 RXRA (0.62) NR1H2NR1H3RXRABACE1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998986-B2 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors EXELIXIS, INC. 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181420-A1 Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors NR1H2, NR1H3, NCOA1 NR1H2 1/4885NR1H3 2/4885RXRA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.